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Summary
Invasive candidiasis (IC) is associated with high mortality in
intensive care unit (ICU) patients. Timely diagnosis of this
potentially fatal condition remains a challenge; on the other
hand, the criteria for initiating empirical antifungal therapy
in critically ill patients are not well defined in different
patient population and ICU settings. Alongside the inter-
national guidelines, reaching regional and local consensus
on diagnosis and management of IC in ICU setting is essen-
tial. This report summarizes our present status of IC man-
agement in ICU, considered by a group of Iranian experts in
the fields of intensive care and infectious diseases. A round
table of 17 experts was held to review the available data
and discuss the optimal treatment strategies for IC in crit-
ical care setting. Comparative published data on the man-
agement of IC were analytically reviewed and the
commonly asked questions about the management of IC
in ICU were isolated. These questions were interactively
discussed by the panel and audience responses were taken
to consolidate point-to-point agreement with the panel
arriving at consensus in many instances. The responses
indicated that patients’ risk stratification, clinical discretion,
fungal diagnostic techniques and the empirical therapy for
IC are likely to save more patients. Treatment options were
recommended to be based on the disease severity, prior
azole exposure, and the presence of suspected azole-
resistant Candida species. This report was reviewed,
edited and discussed by all participants to include further
evidence-based insights. The panel expects such endorsed
recommendations to be soon formulated for implementa-
tion across the country.
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Introduction
Antifungal therapy in high-risk patients with severe
sepsis is often started in the absence of proven disease
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and mainly based on the high clinical suspicion for
invasive fungal infections (IFIs).1 The local epidemi-
ology for fungal infections and the prevalence for
each of the species at a given care facility may provide
physicians with useful clues for the empirical treat-
ment of such infections. In the intensive care unit
(ICU) setting, a timely treatment approach for
fungal infections is often mandated due to the high
mortality attributed to invasive candidiasis (IC) and
the lack of precise and reliable diagnostic tools for
this condition.2–4 It is often not possible to wait for
the culture results and the empirical approach
becomes warranted. This treatment strategy is
shown to result in reduced IFI-related mortality
in ICU.1,3,5
Taken into consideration the international guide-
lines, arriving at a consensus by Iranian intensive care
and infectious diseases experts was deemed necessary
in order to improve our current situation in the diag-
nosis and management of IC in critical care settings.
Accordingly, experts from the two disciplines of crit-
ical care medicine and infectious diseases attended a
round table discussion on 28 July 2013. This report
provides a brief review of the literature published by
both international and local ﬁeld authorities on the
role which IFI plays in mortality and morbidity of
ICU patients. The applicable predictive and diagnos-
tic tools and their place in the clinical management
approaches, based on the current international guide-
lines, were addressed. The consensus from the
experts’ panel which is outlined in the present
report revolved around three pivotal issues: (1)
when to suspect and how to diagnose IFI in ICU
setting? (2) when to start prophylactic, preemptive
and empirical treatment? and (3) what treatment
options to take?
IFIs in ICU: how big is the problem?
IFIs have dramatically increased over the past 20
years. Some contributors to this rise are thought to
be the aging population with life sustaining therapies
such as widespread use of broad spectrum antimicro-
bial therapy and the emergence of resistant micro-
organisms, hemodialysis, widely used invasive
medical devices, bone marrow transplantation, solid
organ transplantation, chemotherapy regimens
and HIV.6
The major risk factors for developing IFI include
prior antibiotic use, central venous catheterization,
total parenteral nutrition (TPN), a recent major sur-
gery, use of steroids, dialysis and immunosuppres-
sion.7 ICU length of stay is considered to be an
important risk factor with the rate of infections not-
ably rising after seven to 10 days.8
IC is the fourth leading cause of bloodstream
infections and the most common IFI accounting for
70–90% of all invasive mycoses9 with increased cost,
morbidity and mortality, especially in ICUs.10
Studies have indicated IC occurring seven to 15
times more frequently than aspergillosis.11 It has
been estimated that up to 10% of nosocomial disease
is attributed to candida infections12 and almost half
of all candida infections occur in ICU.13 In other
words, the incidence of IC in ICU appears to be
almost 10 times bigger than the medical or surgical
wards.10,13,14
Epidemiological insights and the treatment
rationale
Candida albicans and Aspergillus fumigatus are the
main pathogens responsible for IFIs. In ICU patients
however, candida infection accounts for the most
prevalent cause of IFIs.1,10 Together with the growing
incidence of IC in critically ill patients, the spectrum
of pathogenic Candida species has also been chan-
ging. Although Candida albicans (accounting for
40–60% of IC) is still the most common pathogen,
there has been a signiﬁcant recent shift towards non-
albicans strains, i.e. Candida glabrata, Candida tropi-
calis and Candida Krusei causing infection in 20–30%
of cases.15,16 This change in the epidemiological pat-
terns may at least be partly due to the widespread
prophylactic and therapeutic use of ﬂuconazole.17
In ICU patients, infection with C. glabrata is shown
to be associated with relatively higher mortality than
other Candida spp.15 Studies on the rate of attribut-
able mortality of invasive candidemia in diﬀerent
subtypes have shown that C. glabrata and Candida
Krusei are the main subtypes resulting in a mortality
rates of more than 50%.18
With an overall estimated mortality rate of 50–
75% and 40% for invasive aspergillosis and IC,
respectively, IFI imposes a signiﬁcant healthcare
cost burden.19 Particularly in ICU patients, the high
incidence rate of IC (9.8 per 1000 admissions) carry-
ing high morbidity (increased length of stay up to 22
days) and mortality rate (almost 30–40%) consumes
a signiﬁcant share of limited resource.20–22 A recent
study substantiated that patients with and without
candidemia had an ICU crude mortality rate of
52.6% versus 20.6%, respectively (p< 0.001).23
A local report on nosocomial fungal infections in
ICU and transplant wards revealed that most preva-
lent fungal infections appear to result from Candida
albicans, Penicillium spp., Aspergillus niger, and
Cladosporium spp. where environmental fungal con-
tamination was shown to be more prominent in ICU.
Moreover, the length of hospital stay was shown to
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play a major role in colonization of fungi in critical
care settings.24
In other local studies on fungal infections in chil-
dren with advanced kidney disease undergoing peri-
toneal dialysis25 and adults with kidney
transplantation,26 the role of Candida spp. was
shown to be dominant. Furthermore, a multi-centre
analysis on the prevalence of IFIs as deep-seated
mycosis through direct and culture examinations
in immunocompromised hosts (in Tehran, Iran)
revealed that Candida spp. tend to be isolated in
70.4% (39.4% C. albicans and 30.9% non-albincans)
and Aspergillus spp. in 14.1% of the examined
cases.27 Our so far available epidemiological data in
Iran appear to be more or less in line with those
international rates.28,29
Given the above insights on the prevalence of IFI
in critical care setting, the key issue helping to reduce
the heavy burden imposed by IC is known to be
timely and appropriate interventions. Diﬀerent stu-
dies30,31 have indicated that IFIs’ wide range of mor-
tality rates (22–97%) mainly depends on the time of
intervention.
Prompt clinical suspicion and timely diagnosis of
IC still remains a challenge as fungal cultures and
sensitivity may not be readily available globally,
fungal cultures and non-culture-based diagnostic
tools lack necessary sensitivities and in many
instances awaiting cultures or other paraclinical
reports could potentially delay deﬁnitive manage-
ment. Therefore, clinical predictive rules and scoring
systems could act as a bridge to prevent detrimental
delays in instituting management with its antecedent
increase in morbidity and mortality.
With regard to antifungal therapy timing, the
empirical approach guided by practical experience,
observation and non-speciﬁc evidence in a given
high-risk patient, is clinically supported by diﬀerent
authors.3,21,22,31 Therefore, the risk factors for IC in
critically ill ICU patients should be well deﬁned and
the population at highest risk should be targeted
promptly for empiric therapy regardless of the avail-
ability of the paraclinical reports or deﬁnitive diag-
nosis.32,33 The empirical approach which mostly
depends on clinical suspicion is shown to result in
better outcome in high-risk patients admitted to
ICU.1,3,10
The recent increase in ﬂuconazole-resistant
Candida species has encouraged the use of other anti-
fungals such as echinicandins.17,34 The high activity,
broad spectrum and low toxicity proﬁle of these
agents, of which caspofungin is currently available
in Iran, make them ideal agents for empirical use
against IC.35,36 The most recent IDSA (Infectious
Disease Society of America)35 and ESCMID
(European Society for Clinical Microbiology and
Infectious Diseases)34 guidelines have recommended
the empirical antifungal therapy in critically ill
patients with risk factors for IC without any other
known cause for fever.
Given the high mortality, other than the empirical
approach, prophylactic and preemptive therapy
might become indicated in distinct high-risk popula-
tions for candida infection.4 With regard to the tar-
geted therapy, upon documentation of candidemia,
the infecting strains should be identiﬁed for appropri-
ate therapy as Candida species are variably suscep-
tible to diﬀerent antifungals.37
The above insights reemphasize the clinical
burden and the signiﬁcance of appropriate clinical
decision making on therapeutic approaches in IFI
within ICU. As substantiated in an earlier consensus
report from a group of infectious disease experts in
Iran, early initiation of antifungal therapy may
reduce the IFI burden in ICU; however, the wide-
spread use of the available therapeutic options
should be balanced against their cost and beneﬁts
as well as the potential emergence of resistance.
After all, the empirical antifungal therapy approach
was considered a strongly recommended approach in
this report.38
IC in ICU-admitted patients, the implications
of available scoring systems
According to a recent survey, 50–80% of the critically
ill patients who were admitted to ICU had already
been exposed to risk factors for IC, 5–15% had can-
dida colonization on admission and 5–30% actually
had IC.29 In the presence of such a clinical prevalence
and impact, the diagnosis of IC in critically ill
patients remains diﬃcult. Both culture and non-
culture-based diagnostic measures are subject to
noticeable pitfalls.
Cultures from non-sterile sites are mainly colon-
ization and blood cultures for candidemia become
positive in only half of the cases.28 Despite this lack
of sensitivity, fungal blood culture remains the gold
standard for IC diagnosis. Culture-based diagnosis
and species identiﬁcation is time-consuming and
dependence on the culture results only delays
therapy.28,39 Nevertheless, newly introduced non-
culture-based techniques such as 1,3 -b-D-glucan
(1,3-BG) detection, C. albicans germ tube antibodies
(CAGTA), Mannan-antigen plus anti-Mannan-anti-
body measurement, ﬂorescent in situ hybridization
(FISH), matrix-assisted laser desorption ionization
time of ﬂight mass-spectroscopy (MALDITOF-MS)
and Pan-fungus polymerase chain reaction (PCR)
are shown to provide some clinical value in IFI
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diagnosis.39 However, many of these techniques have
demonstrated unacceptably low sensitivity or speciﬁ-
city and are not commercially available in
many settings. These investigatory tools thus need
to undergo further trials for their clinical
validation.40–42
The 1,3-BG test is shown to have false-positive
results among ICU patients with a generally low
(<70%) speciﬁcity in hospitalized patients. Some of
the main attributable factors for the false-positive
results of this test are hemodialysis, gauze contamin-
ation during surgery, intravenous immunoglobulin
(IVIG) administration, bacterial infections, and
the use of antimicrobial drugs such as colistin, erta-
penem, cefazolin, cefotaxime and ampicillin-
sulbactam.39,40
Given the above and based on the earlier insights
on the incidence of IC among high-risk ICU patients,
some risk prediction models have been
developed.5,10,43,44
The most popular prediction rule and scoring
system for IC in non-neutropenic adult patients are
Ostrosky-Zeichner model45and Candida Score.44
According to Ostrosky-Zeichner prediction rule
with the sensitivity, speciﬁcity, positive predictive
value and negative predictive value of 34%, 90%,
10% and 97%, respectively, patients with indwelling
central venous catheters who have received systemic
antibiotics and have at least two of the following:
TPN, any dialysis, any major surgery, pancreatitis,
any steroid therapy or immunosuppression, are con-
sidered potentially high risk to develop IC.10,45
Candida Score is based on the presence or absence
of conditions (with the coeﬃcient b or individual risk
scores in brackets) such as TPN (0.908), surgery on
ICU admission (0.997), multi-focal Candida spp. col-
onization (1.112) and severe sepsis (2.038). Patients
with a score of >2.5 are at high risk for development
of IC.44 With the sensitivity of 81% and speciﬁcity of
74%, one may only need the presence of sepsis and
any one of the three other remaining risk factors or
the presence of all of them together except sepsis in
order to consider starting antifungal treatment for a
particular patient.32,44
The clinical suspicion for IC based on these scor-
ing systems can provide physicians with an easy tool
for timely administration of an appropriate antifun-
gal agent.44,45
Therapeutic approaches in IC, the position
of international guidelines
Therapeutic approaches for IC are mainly formulated
based on risk factors identiﬁcation, early diagnostic
testing or the deﬁnitive diagnosis. As such, patients
might receive antifungal agents as prophylaxis, pre-
emptive, empirical or targeted therapy. Figure 1 illus-
trates a simple scheme for these approaches.31,46,47
According to the most recent IDSA guideline,35
the empirical therapy against IC in non-neutropenic
adult patients should include ﬂuconazole for the less
critically ill patient with no recent azole exposure,
and echinicandins (caspofungin, micafungin and ani-
dulafungin) for moderate to severely ill patients or
those with recent azole exposure. Amphotericin B
(AmB) or its lipid formulation (L-AmB) is considered
Figure 1. Management strategies for invasive candidiasis. In critically ill and high-risk patients, early initiation of antifungal therapy
is shown to reduce mortality. Courtesy of Zaragoza R and Peman J, 2008, subject to creative commons license.
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when other antifungals are not tolerated. Given
the potential side eﬀects, ESCMID guidelines
have not recommended amphotericin B
deoxycholate for any indication for the management
of IC.34 Table 1 summarizes the therapeutic options
for treating IC in non-neutropenic adult patients with
moderate to severe illness, based on recommenda-
tions from the American Thoracic Society48 and
IDSA guidelines.35
Recent outcome prediction studies have indicated
adverse outcome predictors such as ICU length of
stay, renal insuﬃciency, thrombocytopenia, hemato-
logical malignancies, need for mechanical ventilation,
needs for inotropic support, APACHE II (Acute
Physiology and Chronic Health Evaluation II) score
of >20 at the time of candidemia, inadequate empiric
antibiotic treatment and delay in starting antifungal
therapy.3,31,49
Taken together, since delayed treatment leads to
an unacceptably high mortality with a signiﬁcant
human and economic burden,31 prompt diagnosis
and management should be sought. Application of
the validated scoring systems such as Candida
Score44 and Ostrosky-Zeichner model5,10,45 in ICU
will help clinicians to identify the high-risk patients
who substantially beneﬁt from prompt treatment
against IC. Meanwhile, utilizing the evolving
diagnostic strategies and modalities as well as the
expanding antifungal armamentarium can be justiﬁed
through continuous research in the ﬁeld.
Literature review, participants and the
consensus method
To gather evidence, we started from a literature
review on the management strategies for IFIs in crit-
ical care setting. To do so, databases including
MEDLINE (PubMed), Scopus and Google Scholar
were searched and relevant papers together with the
most recent international practice guidelines on the
management of IC in ICU were retrieved and circu-
lated amongst invited panelists. All contributors had
reviewed the resources before attending this experts’
input forum.
The panel comprised 17 experts (intensive care and
infectious diseases specialists) from diﬀerent medical
care centres and universities in Tehran, Iran. Each was
invited based on his/her expertise in the management
of IC and other fungal infections in critical care set-
ting. Following plenary talks, interactive discussion
and review of literature, three pivotal and commonly
asked questions were dealt with. Audience responses
and supporting evidence were put together to
Table 1. Summary of the ATS and IDSA guidelines for treating invasive candidiasis in critically ill patients.
Disease manifestation American Thoracic Society (ATS) guideline
Infectious Disease Society of America
(IDSA) guideline
Candidemia,
Clinically unstable;
moderate to severe illness
Amphotericin B deoxycholate
(0.6–1.0mg/kg/d) or lipid-based ampho-
tericin B (3–5mg/kg/d)
OR
Caspofungin (70mg IV loading dose day 1,
then 50mg/d, IV)
OR
Micafungin (100mg/d, IV)
OR
Anidulafungin (200mg on day 1, then
100mg/d, IV)
OR
Voriconazole (6mg/kg/12 h x2, then 3mg/
kg/12 h)
OR
High-dose Fluconazole (800mg/d) and
Amphotericin B (0.6–1.0mg/kg/d)
OR
A combination of Fluconazole (800mg/d)
and Amphotericin B (0.6–1.0mg/kg/d) for
the first 5–6 d.
First-line treatment
Caspofungin (70mg IV loading dose day 1,
then 50mg/d, IV)
OR
Micafungin (100mg/d, IV)
OR
Anidulafungin (200mg on day 1, then
100mg/d, IV)
Alternative regimen
Fluconazole 800mg IV, loading dose; then
400mg/d, IV or PO
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consolidate point-to-point agreement. For most
instances, the expert panel could draw an agreed-
upon pathway. One of the authors consolidated the
experts’ comments and later, circulated the decision
checklist amongst the panelists for endorsement. The
clinical algorithmic approach which was agreed by the
panel to be followed for the management of IC in the
critical care setting (as detailed in the result section of
the current report) is summarized in Figure 2.
The manuscript generated from this experts’ meet-
ing was distributed, reviewed and edited by all par-
ticipants. The current expert opinion report as well as
Figure 2. The algorithmic approach for the management of invasive candidiasis in critical care setting, agreed upon by the Iranian
ICU panel of experts. For referencing and further justifications please see the results section. IC: invasive candidiasis; AmB:
Amphotericin B; LAmB: Liposomal Amphotericin B; PCR: polymerase chain reaction; 1,3-BG: 1,3-beta-D glucan; IFI: invasive fungal
infections.
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future local recommendation documents on the man-
agement of IC in critically ill patients (on the basis of
the present consensus) will be formulated as a local
recommendation and is expected to be implemented
across the country following necessary endorsements
from national health authorities and the allied scien-
tiﬁc societies.
Results
How to diagnose IC?
Discussion. Since the local epidemiological data on
fungal infections in ICU are still lacking, our perspec-
tive of the incidence and the impact of IFIs in our
ICUs should be further clariﬁed in future investiga-
tions. The IC scoring systems and predictive models
are not used commonly in our setting and many clin-
icians seem not to be conversant with these tools.
Some believe that due to the relatively low sensitivity
of such scoring systems and risk prediction models
and the high number needed to treat, ancillary testing
such as 1,3-BG and PCR should be utilized instead.
On the other hand, many others rely more on the
signiﬁcance of clinical suspicion and the value of
Candida Score as one of the most applicable tools
for high-risk patient selection.
As such, when ancillary tests are neither available
nor reliable, the use of risk prediction models and
scoring tools such as ‘Candida Score’ would distin-
guish patients who are at markedly increased risk for
IC. The appropriate treatment can then be empiric-
ally administered.
Responses. Majority (13/17) of the panel agreed that
due to the lack of availability and reliability (lab-
to-lab variation) of such tests, although they are
good to have, clinicians should depend on their clin-
ical suspicion and proceed to empirical antifungal
therapy against IC. This applies to critically ill
patients or those characterized as high risk for IC,
based on the available validated scoring systems
namely the Candida Score. At the same time, more
precise and guideline-oriented clinical evaluations
should be implemented to curb the overuse of anti-
fungal agents in the critical care setting.
Introducing these clinical scoring systems to less
experienced physicians in the ﬁeld and increasing
their awareness about the use and misuse of antifun-
gals based on the current evidence will be crucial. The
ancillary investigations such as PCR and 1,3-BG
can also be considered based on their availability,
reliability (reference labs) and cost-utility
justiﬁcation (Figure 2).
When to start therapy? The prophylactic,
preemptive and empirical approaches
Discussion. The concept of preemptive and empirical
therapy could overlap in many situations. When we
intend to empirically treat IC in non-neutropenic and
non-transplanted patients, some key issues such as
how early is early and how long to continue treat-
ment should be made as clear as possible. In an
ICU-admitted patient who continues to exhibit
signs of systemic inﬂammatory response following
4–7 days of ICU stay with appropriate and adequate
antibiotic therapy, institution of empirical antifungals
for IC is warranted. It also holds true for patients just
admitted to ICU or transferred from another facility
with his/her clinical state over the past 4–7 days prior
to ICU transfer consistent with ongoing infection.
This discretion however depends on the clinical judg-
ment of the treating physician.4,35
Other than the empirical approach, some non-
neutropenic patients are appropriate candidates for
prophylactic antifungal therapy. A patient with
major abdominal surgery admitted to ICU is a typical
example.4
Time to start antifungal therapy for high-risk
patients is the crucial point with a signiﬁcant value
in patients’ outcome.31 In a high-risk and critically ill
patient, empirical therapy for IC is not only an essen-
tial component of the immediate management but
also is part of care continuity. When culture results
become available and a distinct strain is recovered,
the treatment regimen can be adjusted.20
The duration of empirical antifungal therapy
should be at least 14 days (14 days since the beginning
of therapy or 14 days following a negative culture
result).34,35
Responses. All the experts (17/17) agreed that timely
treatment against IC in potentially high-risk patients
is crucial. When a patient acquires the score of more
than 2.5 in Candida Score and stays for over 4–7 days
in ICU, empirical therapy should be strongly encour-
aged. Treatment should continue for at least 14 days
(Figure 2).
What treatment options to use? The question of
susceptibility, availability and cost versus utility
Discussion. Considering the availability of the treat-
ment options, we should be able to follow the algo-
rithmic approach laid down by the international
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guidelines. The decisions should however be adjusted
and individualized based on speciﬁc limitations such
as the availability of the treatment options, cost-
utility rationale and tolerability of the given regimen
in distinct patients. When high-risk patients for IC are
stable and the disease is not severe, patients should be
treated with ﬂuconazole if not recently exposed to
azoles. In case of prior azole exposure or presumed
infection with C. glabrata or C. krusei, echinicandins
(caspofungin which is the only echinicandin currently
available in Iran) will be the antifungal of choice.35
In case the patient who is at risk for IC is critically
ill and hemodynamically unstable, caspofungin is the
ﬁrst-line therapy. Although ESCMID guideline34 has
recommended not to use AmB for any indication in
these population due to its potential side eﬀects, it
should still be an alternative modality against IC
when other therapies are not available or poorly tole-
rated. Local studies are needed to evaluate the cost
versus utility of the above therapeutic options against
IC in ICU.
Responses. A majority of the panelists (15/17) agreed
that empirical therapy is indicated in some subset of
ICU patients including those with unexplained sepsis.
The decision depends on the candida colonization (at
multiple sites) and some other risk factors in the
absence of any explained cause for fever. Given the
correlation between delay in initiation of anti-fungal
therapy and mortality in IC patients, everyone agreed
that the most eﬀective antifungal agent (as deﬁned by
the guidelines) should be employed empirically.
Caspofungin, L-AmB and Fluconazole are in turn
the mostly recommended antifungals for the empir-
ical therapy against IC in ICU38 (Figure 2).
Conclusive remarks
All panelists participating in the experts’ meeting for
the management of IC in critical care setting were in
consensus on the need to promptly identify and
manage high-risk patients for IC in ICU. Risk strati-
ﬁcation, clinical discretion and the use of validated
scoring systems such as the Candida Score are the key
to choosing the right patients for empirical antifungal
therapy against IC.
International guideline clauses seem to be partly
applicable to our local practice. Although there
were swings away from AmB in such guidelines, it
still should remain in the armamentarium of IC man-
agement in our ICU practice. Treatment strategies
can be modiﬁed on a case by case basis depending
on recent azole exposure, severity of the underlying
illness and the extent of infection.
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